MIT’s implantable device could help docs determine best cancer medicine(Boston Business Journal)
Removing the trial and error associated with cancer drug treatments is high on oncologists’ wish lists. Heeding that call, MIT has developed an implantable device (about the size of a grain of rice) that can carry up to 30 different drug doses to a cancerous tumor, and then be removed to test responses.
Brain tumors, traumatic head injury and a number of brain and nervous system conditions can cause pressure to build up inside the skull. As intracranial pressure (ICP) rises, it can compress the brain and result in swelling of the optic nerves, damaging brain tissue and causing irreversible vision loss.
That’s what nearly happened to a 13-year-old boy who had three weeks of uncontrolled headaches and sudden double vision. His neuro-ophthalmologist at Boston Children’s Hospital, Gena Heidary, MD, PhD, found reduced vision in the right eye, along with poor peripheral vision, an enlarged blind spot and swelling of both optic nerves.
As Heidary suspected, he had idiopathic intracranial hypertension, a condition that can raise ICP both in children and adults. Heidary performed an operation around the optic nerve to relieve the pressure, and vision in the boy’s right eye gradually improved, though not completely. Heidary has had to monitor his ICP ever since to protect his visual system from further irreversible damage.
Unfortunately, such monitoring currently is pretty invasive.
Silk production and global interest in the lustrous fiber date back to prehistoric times. Today, the natural protein is solidifying itself as a biomaterials alternative in the world of regenerative medicine.
Some great inventions were on view this week at the second annual Boston Children’s Hospital Innovators Showcase. Hosted by the hospital’s Innovation Acceleration Program and Technology & Innovation Development Office, the event featured everything from virtual reality goggles with gesture control to biomedical technologies. Below are a few new projects that caught Vector’s eye (expect to hear more about them in the coming months), a kid-friendly interview about the SimLab and list of inventions kids themselves would like to see. (Photos by Katherine Cohen except as noted)
Exome sequencing comes to the clinic (JAMA)
An approachable and thorough summary of the growing trend, describing the ways in which sequencing can help provide a diagnosis, the diagnostic yield (as high as 40 percent or more, depending on the population), how often the results have changed treatment decisions and the question of who pays.
Who Owns CRISPR? (The Scientist)
Excellent coverage of the escalating patent scramble for genome editing.
(Clockwise from top: T3, Surgical Sam, non-electric baby warmer, silk-based organ reconstruction)
Next week—on April 15—Boston-area visitors can sample inventions and technologies from around Boston Children’s Hospital, some in development and some already in use. More than 20 medical innovations will be on display in an interactive “science fair” format. We’ll be demonstrating a variety of medical devices, mobile applications, software IT innovations, wearables and bioengineering innovations. It’s free and open to the public.
Jason Kahn, PhD, is a co-founder of Neuro’motion, a research associate at Boston Children’s Hospital, and a part-time instructor at Harvard Medical School.
Earlier this month, I traveled to SXSW Interactive 2015 to introduce my company, Neuro’motion. We build mobile video games and toys to build emotional strength in children, improve access to mental health care and provide a drug-free alternative for behavioral health. We were born from research at Boston Children’s Hospital and our mission is to get our games into as many people’s hands as possible.
Bubble wrap used for cheap blood and bacteria tests(New Scientist)
Snap, crackle, pop are the familiar sounds of bubble wrap. According to George Whitesides at the Wyss Institute for Biologically Inspired Engineering at Harvard University, the cheap packing material may be popping up in the near future as a diagnostic tool, replacing costlier 96-well plates.
Nearly half of all pre-schoolers with ADHD are on medication(Washington Post)
The American Academy of Pediatrics calls for children under 6 with ADHD to engage in behavioral therapy before taking medication. Yet according to a national survey published in the Journal of Pediatrics, nearly half of preschool-aged children are on medication for the condition, and more than a fifth were receiving neither of the recommended therapies.
Device developers tend to focus on the FDA approval process—PMAs and 510(k) clearances—while overlooking another major challenge: getting insurers to cover the device. Before approaching investors, and certainly before doing any studies, keep payers in mind, advises Maren Anderson, president of MDA Consulting, Inc., which specializes in reimbursement planning.
In the old days, doctors prescribed, and insurers paid. Under health care reform, that’s changed, says Anderson.